(Exact name of registrant as specified in its charter)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

In connection with this name change to TapImmune Inc., as of the open of business on June 28, 2007, the Company has the following new CUSIP number and trading symbol:

With an effective date of June 28, 2007 (the "Effective Date") and a distribution date of June 29, 2007, the Board of Directors (the "Board") of the Company unanimously resolved, in accordance with Section 78.207 of the Nevada Revised Statutes: Chapter 78, as amended, to decrease the number of shares of the Company's authorized share capital and correspondingly decrease the number of issued and outstanding common shares, in each case on a one (1) new share for 2.5 old shares basis (the "Decrease in Authorized Share Capital/Reverse Stock Split").

The Decrease in Authorized Share Capital/Reverse Stock Split was implemented taking into account the Company's authorized share capital and number of issued and outstanding shares of common stock as of the Effective Date. As such, the Company's authorized share capital was decreased from 200,000,000 common shares to 80,000,000 common shares and the Company's issued and outstanding common stock was decreased from 57,353,126 common shares to 22,941,250 common shares. The par value of the Company's common shares, which is $0.001 per common share, has not changed.

Shareholders should retain their existing share certificates and not return their share certificates to the Company's transfer agent. Share certificates representing the Reverse Stock Split will be mailed out to registered shareholders as of the Effective Date.

- 2 -

The Company is ascribing no monetary value to Decrease in Authorized Share Capital/Reverse Stock Split. Accordingly, there should be no tax payable by Canadian or U.S. shareholders as a result of the Decrease in Authorized Share Capital/Reverse Stock Split. Shareholders are advised to contact their own tax advisors for further information.

Investors are cautioned that trading in the securities of the Company should be considered highly speculative. No exchange, over-the-counter market or regulatory authority has in any way passed upon the merits of the Decrease in Authorized Share Capital/Reverse Stock Split or has either approved or disapproved the contents of this Current Report.

Not applicable.

(b)       Pro forma financial information.

Not applicable.

(c)       Shell company transactions.

Not applicable.

(d)       Exhibits.

99.1     News Release of the Company dated June 28, 2007.

__________

- 3 -

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

__________

- 4 -

The Company (previously GeneMax Corp) had been operating under an exclusive world-wide license from The University of British Columbia (UBC) for the use of TAP as an immunotherapy in the treatment of a broad spectrum of metastatic cancers deficient in this molecule. Initial animal studies have shown that restoring TAP can significantly improve outcomes and survival by up to 70%. This technology was discovered by Dr. Wilf Jefferies, a world expert in and professor of Immunology and Microbiology at the Michael Smith Laboratories at The UBC.

In addition, the use of TAP as a molecular adjuvant for reviving and optimizing vaccines against infectious disease was also discovered. This exciting discovery has far reaching potential applications in fighting and eradicating viral diseases in humans and many additional veterinary applications. The initial proof of concept studies showed a 100 to 1000 fold increase in the potency of a targeted vaccine.

The Company is preparing to move its technology to its own facilities and to advance the pre-clinical programs of its core TAP technologies into GLP clinical programs.

In conjunction with the new name, the company has restructured the capital of the company in a 1 for 2.5 consolidation.

About TAP

Transporters Associated with Antigen Processing (TAP) are transporters responsible for supplying tumor-associated antigens and viral antigens used in the assembly of MHC class I surface molecules.   MHC class I molecules are required for the recognition and destruction of tumor cells and virus infected cells by the cellular arm of the immune system.    A wide variety of metastatic cancers evade destruction by the immune system due to absent or insufficient amounts of TAP, making the tumors unrecognizable by the immune system.  The TAP molecule also works as an adjuvant to enhance vaccines against infectious diseases.